MedTrace Logo

Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh

NCT00607074 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2008-02-05

No results posted yet for this study

Summary

This longitudinal study aimed to assess whether regular anti-Giardia and antihelmintic treatment improved growth and small intestinal mucosal function of rural Bangladeshi infants.

Conditions

  • Giardiasis

Interventions

DRUG

Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)

Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)

DRUG

Anti-Giardia treatment only (secnidazole or albendazole)

Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole

DRUG

Control group (placebo)

Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo

Sponsors & Collaborators

Principal Investigators

  • Nicholas C Mascie-Taylor, ScD · Department of Biological Anthropology, University of Cambridge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Months
Max Age
15 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2004-04-30
Completion
2006-12-31

Countries

  • Bangladesh

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607074 on ClinicalTrials.gov